CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Zidovudinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000965
NCT00000965N/ACompleted
CompareCT.gov

Pharmacokinetics of Total Phosphorylated Zidovudine in Mononuclear Cells From HIV-Infected Patients

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Mar 1, 2011

In Brief

A clinical study evaluating Zidovudine for HIV Infections. Completed, across 1 site.

Detailed Summary

To define the pharmacokinetic parameters (blood levels) of total phosphorylated zidovudine (AZT) in peripheral blood mononuclear cells (PBMC) from HIV-infected patients. Despite an understanding of the serum (or plasma) pharmacokinetics (blood levels) of AZT, a therapeutic concentration range and optimal dosing interval have not yet been determined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsGlaxo Wellcome

Timeline

N/ACompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Primary CompletionAug 1, 1993
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Zidovudinedrug